Healthcor Management, L.P. 13F annual report
Healthcor Management, L.P. is an investment fund managing more than $800 million ran by Laurie Hadick. There are currently 54 companies in Mrs. Hadick’s portfolio. The largest investments include Biomarin Pharmaceutical and Abbvie Inc, together worth $106 million.
$800 million Assets Under Management (AUM)
As of 7th November 2022, Healthcor Management, L.P.’s top holding is 759,038 shares of Biomarin Pharmaceutical currently worth over $64.3 million and making up 8.0% of the portfolio value.
Relative to the number of outstanding shares of Biomarin Pharmaceutical, Healthcor Management, L.P. owns more than approximately 0.1% of the company.
In addition, the fund holds 310,250 shares of Abbvie Inc worth $41.6 million, whose value fell approximately 0.1% in the past six months.
The third-largest holding is Agilent Technologies worth $41.1 million and the next is Boston Scientific worth $37.1 million, with 958,600 shares owned.
Currently, Healthcor Management, L.P.'s portfolio is worth at least $800 million. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Healthcor Management, L.P.
The Healthcor Management, L.P. office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Laurie Hadick serves as the Chief Compliance Officer at Healthcor Management, L.P..
Recent trades
In the most recent 13F filing, Healthcor Management, L.P. revealed that it had opened a new position in
Abbvie Inc and bought 310,250 shares worth $41.6 million.
This means they effectively own approximately 0.1% of the company.
Abbvie Inc makes up
6.3%
of the fund's Health Care sector allocation and has decreased its share price by approximately 0.1% in the past year.
The investment fund also strengthened its position in Biomarin Pharmaceutical by buying
18,090 additional shares.
This makes their stake in Biomarin Pharmaceutical total 759,038 shares worth $64.3 million.
Biomarin Pharmaceutical dropped approximately 0.1% in the past year.
On the other hand, there are companies that Healthcor Management, L.P. is getting rid of from its portfolio.
Healthcor Management, L.P. closed its position in ChemoCentryx Inc on 14th November 2022.
It sold the previously owned 1,097,370 shares for $27.2 million.
Laurie Hadick also disclosed a decreased stake in Boston Scientific by 0.5%.
This leaves the value of the investment at $37.1 million and 958,600 shares.
One of the average hedge funds
The two most similar investment funds to Healthcor Management, L.P. are Fiduciary and Foster Dykema Cabot & Co Inc/ma. They manage $800 million and $800 million respectively.
Laurie Hadick investment strategy
Healthcor Management, L.P.’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 82.5% of
the total portfolio value.
The fund focuses on investments in the United States as
72.2% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
41% of the total holdings value.
On the other hand, small-cap stocks make up only 1.9% of the portfolio.
The average market cap of the portfolio companies is close to $51.9 billion.
The complete list of Healthcor Management, L.P. trades based on 13F SEC filings
These positions were updated on November 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Biomarin Pharmaceutical Inc. |
2.44%
759,038
|
$64,344,000 | 8.05% |
| Abbvie Inc |
Opened
310,250
|
$41,639,000 | 5.21% |
| Agilent Technologies Inc. |
144.45%
338,030
|
$41,088,000 | 5.14% |
| Boston Scientific Corp. |
46.98%
958,600
|
$37,127,000 | 4.64% |
| Lilly Eli & Co |
46.04%
103,150
|
$33,354,000 | 4.17% |
| Amerisourcebergen Corp |
52.41%
239,150
|
$32,364,000 | 4.05% |
| Unitedhealth Group Inc |
7.69%
62,980
|
$31,807,000 | 3.98% |
| Danaher Corp. |
21.59%
117,800
|
$30,427,000 | 3.81% |
| ChemoCentryx Inc |
Closed
1,097,370
|
$27,193,000 | |
| Tenet Healthcare Corp. |
No change
518,990
|
$26,770,000 | 3.35% |
| Thermo Fisher Scientific Inc. |
Opened
51,240
|
$25,988,000 | 3.25% |
| Centene Corp. |
44.35%
300,970
|
$23,418,000 | 2.93% |
| Cigna Corp. |
20.28%
76,910
|
$21,340,000 | 2.67% |
| Cytokinetics Inc |
10.51%
434,560
|
$21,054,000 | 2.63% |
| Humana Inc. |
9.11%
42,920
|
$20,824,000 | 2.60% |
| Syndax Pharmaceuticals Inc |
6.95%
859,240
|
$20,648,000 | 2.58% |
| Dexcom Inc |
238.99%
253,500
|
$20,417,000 | 2.55% |
| Biogen Inc |
83.09%
69,950
|
$18,677,000 | 2.34% |
| Elevance Health Inc |
28.25%
38,910
|
$17,674,000 | 2.21% |
| AMGEN Inc. |
Opened
75,370
|
$16,988,000 | 2.12% |
| LivaNova PLC |
32.58%
328,030
|
$16,654,000 | 2.08% |
| Henry Schein Inc. |
No change
248,920
|
$16,371,000 | 2.05% |
| Bristol-Myers Squibb Co. |
45.89%
223,150
|
$15,864,000 | 1.98% |
| Incyte Corp. |
2.68%
227,851
|
$15,184,000 | 1.90% |
| Intuitive Surgical Inc |
Closed
72,490
|
$14,549,000 | |
| Horizon Therapeutics Pub L |
74.61%
229,530
|
$14,206,000 | 1.78% |
| Becton Dickinson & Co |
12.96%
62,930
|
$14,023,000 | 1.75% |
| Kezar Life Sciences Inc |
32.88%
1,607,650
|
$13,842,000 | 1.73% |
| Universal Hlth Svcs Inc |
Closed
134,040
|
$13,499,000 | |
| CVS Health Corp |
Opened
131,150
|
$12,508,000 | 1.56% |
| Mckesson Corporation |
No change
35,040
|
$11,909,000 | 1.49% |
| Cooper Cos Inc |
Closed
30,770
|
$9,635,000 | |
| Abbott Labs |
50.34%
98,970
|
$9,576,000 | 1.20% |
| Molina Healthcare Inc |
Opened
27,540
|
$9,084,000 | 1.14% |
| Hologic, Inc. |
65.85%
137,330
|
$8,861,000 | 1.11% |
| Seagen Inc |
44.36%
57,340
|
$7,846,000 | 0.98% |
| Zimmer Biomet Holdings Inc |
Closed
72,020
|
$7,566,000 | |
| Rocket Pharmaceuticals Inc |
Opened
445,140
|
$7,104,000 | 0.89% |
| Blueprint Medicines Corp |
Opened
104,600
|
$6,892,000 | 0.86% |
| Inspire Med Sys Inc |
Opened
38,240
|
$6,783,000 | 0.85% |
| Alkermes plc |
Opened
303,500
|
$6,777,000 | 0.85% |
| Ishares Tr |
Closed
53,940
|
$6,345,000 | |
| Immunogen, Inc. |
160.00%
1,300,000
|
$6,214,000 | 0.78% |
| Shockwave Med Inc |
Opened
19,720
|
$5,484,000 | 0.69% |
| Merus N.V |
128.93%
272,890
|
$5,466,000 | 0.68% |
| Chinook Therapeutics, Inc. |
Opened
266,830
|
$5,246,000 | 0.66% |
| DENTSPLY Sirona Inc |
Opened
158,200
|
$4,485,000 | 0.56% |
| Geron Corp. |
90.42%
1,904,234
|
$4,456,000 | 0.56% |
| Select Sector Spdr Tr |
Closed
34,610
|
$4,438,000 | |
| RAPT Therapeutics, Inc. |
Closed
217,165
|
$3,963,000 | |
| Teva Pharmaceutical Inds Ltd |
Closed
499,640
|
$3,757,000 | |
| Affimed N.V. |
No change
1,721,925
|
$3,547,000 | 0.44% |
| Cano Health Inc |
Opened
395,560
|
$3,430,000 | 0.43% |
| Neogenomics Inc. |
Opened
391,110
|
$3,367,000 | 0.42% |
| Quanterix Corp |
Closed
201,560
|
$3,263,000 | |
| Nevro Corp |
Opened
67,600
|
$3,150,000 | 0.39% |
| Galapagos NV |
Closed
55,280
|
$3,085,000 | |
| Bluebird bio Inc |
Opened
455,000
|
$2,880,000 | 0.36% |
| Natera Inc |
92.75%
65,130
|
$2,854,000 | 0.36% |
| Biocryst Pharmaceuticals Inc. |
Closed
239,820
|
$2,537,000 | |
| Neurocrine Biosciences, Inc. |
Opened
21,720
|
$2,307,000 | 0.29% |
| Hyperfine Inc |
No change
2,749,400
|
$2,227,000 | 0.28% |
| Revance Therapeutics Inc |
95.45%
64,590
|
$1,744,000 | 0.22% |
| Insulet Corporation |
Closed
7,150
|
$1,558,000 | |
| Intra-Cellular Therapies Inc |
Closed
27,070
|
$1,545,000 | |
| IVERIC bio Inc |
Opened
85,230
|
$1,529,000 | 0.19% |
| Leap Therapeutics Inc |
No change
1,066,689
|
$939,000 | 0.12% |
| Ikena Oncology Inc |
No change
220,082
|
$781,000 | 0.10% |
| No transactions found | |||
| Showing first 500 out of 68 holdings | |||
Hedge funds similar to Healthcor Management, L.P.
- Courier Capital
- Advance Capital Management
- Nexus Investment Management Ulc
- Dorsey Asset Management
- Newsquare Capital
- Foster Dykema Cabot & Co Inc/ma
- Fiduciary
- Lenox Wealth Advisors
- Woodmont Investment Counsel
- Alpha Wave Global, L.P.
- Weatherbie Capital
- Eagle Ridge Investment Management
- Greenvale Capital LL.P.
- Cavalry Management